High Dose Psilocybin for Post-Traumatic Headache

"This clinical trial has an enrolment of 24 people suffering from cervicogenic headaches and between the ages 21-65. Essential inclusion criteria include that any medication used to treat the condition cannot be taken more than twice a week with triptans."

"This clinical trial's inclusion criteria necessitates that all patients are between 21 and 65 years of age. Conversely, there exist 19 trials specifically for minors under 18 and 120 studies dedicated to elderly individuals over the age of 65."

"In view of sparse clinical data, the safety rating for High Dose Psilocybin was conservatively estimated as a 1."

"According to information available on clinicaltrials.gov, this research trial is currently enlisting participants. It was initially posted on March 28th 2019 and recently amended on July 27th 2022."

"Affirmative, the information on clinicaltrials.gov demonstrates that this research is currently accommodating patient recruitment. This study was first posted on March 28th 2019 and most recently updated on July 27th 2022; with 24 patients needed from a single medical centre."

"This clinical trial's primary endpoint is a modification in the intensity of phonophobia during headaches. Secondary endpoints are shifts from baseline levels of pituitary adenylate cyclase-activating peptide (PACAP), heart rate, and suicide hazard as measured by Columbia Suicide Severity Rating Scale(CSSRS). These data points will be recorded at 0, 1, 2, 4 hours after drug administration plus 24 hours posttreatment."

"Currently, 33 clinical investigations are ongoing that focus on the effects of High Dose Psilocybin. Of these, none have reached Phase 3 yet. Centres running trials for this particular treatment span 36 different locales with a concentration in Vancouver and Washington State."